Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

  • Home
  • 2021
  • July
  • 30
  • Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

Original Source

On July 30, 2021

Post navigation

Previous PostVF Reports First Quarter Fiscal 2022 Results; Raises Full Year Fiscal 2022 Outlook
Next PostMSCI strengthens private asset capabilities with acquisition of Real Capital Analytics

Related Post

August 16, 2022
  • Business News

More than 1,800 customers in Texas assisted through Entergy’s The Power to Care program

August 16, 2022
  • Business News

Modification to Methodology of the S&P/CLX INTER

August 16, 2022
  • Business News

HII CEO Tours Company Operations in Hawaii and Meets with Military and Civilian Leaders

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219